Education
About Us
Working with TipRanks
Follow Us
Celldex Therapeutics Inc (CLDX)
NASDAQ:CLDX
CLDX Analyst Ratings
Strong Buy
8 Buy
1 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
CLDX Stock 12 Month Forecast
Average Price Target
$55.50
▲(122.09% Upside)
| Highest Price Target$78.00 | Average Price Target$55.50 | Lowest Price Target$24.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
TR | OpenAI - 4o
$22→$24
Hold
-3.96%
Downside
Reiterated
08/13/25
LifeSci Capital
$74
Buy
196.12%
Upside
Reiterated
08/12/25
Celldex's Barzolvolimab: A Promising Treatment for Eosinophilic Esophagitis with Market PotentialCelldex (Nasdaq: CLDX) plans to report topline 12-week data in the randomized, double-blind, placebo-controlled Phase 2 study tesng its KIT targeng mAb, barzolvolimab, for eosinophilic esophagis (EoE). Below we discuss the background of EoE, the epidemiology of the disorder, the study design and biologic raonale for tesng barzolvolimab, and the compev e landscape/reference Dupixent and Eohilia datasets for comparison. Given the large size of the EoE populaon (recently esmated at upwards of 472,380 cases in the US) and pricing potenal (Dupixent’s annual WAC in EoE is $95,840 given its QW dosing), we believe this could be a meaningful market opportunity for barzolvolimab, if successful. In addion, a posive readout would add support to the idea of KIT inhibitors working in a wide range of atopic condions. Brief Background on EoE.
Canaccord Genuity
$64
Buy
156.10%
Upside
Reiterated
08/11/25
Morgan Stanley
$43
Buy
72.07%
Upside
Reiterated
08/08/25
H.C. Wainwright
$50
Buy
100.08%
Upside
Reiterated
08/08/25
Leerink Partners
$78
Buy
212.12%
Upside
Reiterated
08/07/25
Analysts Are Bullish on These Healthcare Stocks: Neuren Pharmaceuticals Limited (NURPF), Zymeworks (ZYME)We expect multiple important data readouts for CLDX in 2H25, including Phase 2 EoE data and 20-week CIndU data for barzo, along with initial Phase 1 healthy volunteer data for CDX-622 (SCF/TSLP bispecific). Recall that CLDX recently presented compelling 76-week data from the Phase 2 CSU study for barzo, showing that patients who were off-drug for 24-weeks maintained top-tier efficacy (up to 41% complete response) with reversibility of most on-target AEs (hair color change, hypopigmentation) – reinforcing barzo’s best-in-disease clinical profile in chronic urticarias (see our note HERE for more details). CLDX is currently enrolling the pivotal Phase 3 EMBARQ program (NCT06445023 & and expects enrollment (~915pts per study) to complete by next summer.
Wells Fargo
$44
Buy
76.07%
Upside
Reiterated
08/07/25
Cantor Fitzgerald
$67
Buy
168.11%
Upside
Reiterated
06/13/25
UBS
$44→$38
Buy
52.06%
Upside
Reiterated
05/09/25
Goldman Sachs
$42→$36
Hold
44.06%
Upside
Reiterated
02/28/25
Stifel Nicolaus
$58
Buy
132.09%
Upside
Reiterated
02/28/25
Guggenheim
$90
Buy
260.14%
Upside
Reiterated
01/08/25
Citi
$70
Buy
180.11%
Upside
Reiterated
01/08/25
Wolfe Research
$51
Hold
104.08%
Upside
Downgraded
09/26/24
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
TR | OpenAI - 4o
$22→$24
Hold
-3.96%
Downside
Reiterated
08/13/25
LifeSci Capital
$74
Buy
196.12%
Upside
Reiterated
08/12/25
Celldex's Barzolvolimab: A Promising Treatment for Eosinophilic Esophagitis with Market PotentialCelldex (Nasdaq: CLDX) plans to report topline 12-week data in the randomized, double-blind, placebo-controlled Phase 2 study tesng its KIT targeng mAb, barzolvolimab, for eosinophilic esophagis (EoE). Below we discuss the background of EoE, the epidemiology of the disorder, the study design and biologic raonale for tesng barzolvolimab, and the compev e landscape/reference Dupixent and Eohilia datasets for comparison. Given the large size of the EoE populaon (recently esmated at upwards of 472,380 cases in the US) and pricing potenal (Dupixent’s annual WAC in EoE is $95,840 given its QW dosing), we believe this could be a meaningful market opportunity for barzolvolimab, if successful. In addion, a posive readout would add support to the idea of KIT inhibitors working in a wide range of atopic condions. Brief Background on EoE.
Canaccord Genuity
$64
Buy
156.10%
Upside
Reiterated
08/11/25
Morgan Stanley
$43
Buy
72.07%
Upside
Reiterated
08/08/25
H.C. Wainwright
$50
Buy
100.08%
Upside
Reiterated
08/08/25
Leerink Partners
$78
Buy
212.12%
Upside
Reiterated
08/07/25
Analysts Are Bullish on These Healthcare Stocks: Neuren Pharmaceuticals Limited (NURPF), Zymeworks (ZYME)We expect multiple important data readouts for CLDX in 2H25, including Phase 2 EoE data and 20-week CIndU data for barzo, along with initial Phase 1 healthy volunteer data for CDX-622 (SCF/TSLP bispecific). Recall that CLDX recently presented compelling 76-week data from the Phase 2 CSU study for barzo, showing that patients who were off-drug for 24-weeks maintained top-tier efficacy (up to 41% complete response) with reversibility of most on-target AEs (hair color change, hypopigmentation) – reinforcing barzo’s best-in-disease clinical profile in chronic urticarias (see our note HERE for more details). CLDX is currently enrolling the pivotal Phase 3 EMBARQ program (NCT06445023 & and expects enrollment (~915pts per study) to complete by next summer.
Wells Fargo
$44
Buy
76.07%
Upside
Reiterated
08/07/25
Cantor Fitzgerald
$67
Buy
168.11%
Upside
Reiterated
06/13/25
UBS
$44→$38
Buy
52.06%
Upside
Reiterated
05/09/25
Goldman Sachs
$42→$36
Hold
44.06%
Upside
Reiterated
02/28/25
Stifel Nicolaus
$58
Buy
132.09%
Upside
Reiterated
02/28/25
Guggenheim
$90
Buy
260.14%
Upside
Reiterated
01/08/25
Citi
$70
Buy
180.11%
Upside
Reiterated
01/08/25
Wolfe Research
$51
Hold
104.08%
Upside
Downgraded
09/26/24
Best Analysts Covering Celldex
1 Month
xxx
Success Rate
14/25 ratings generated profit
Average Return
+5.93%
reiterated a xxx
rating 3 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 56.00% of your transactions generating a profit, with an average return of +5.93% per trade.
3 Months
xxx
Success Rate
12/25 ratings generated profit
Average Return
+10.55%
reiterated a xxx
rating 3 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 48.00% of your transactions generating a profit, with an average return of +10.55% per trade.
1 Year
Success Rate
8/17 ratings generated profit
Average Return
+76.20%
reiterated a buy rating 2 months ago
Copying Kristen Kluska's trades and holding each position for 1 Year would result in 47.06% of your transactions generating a profit, with an average return of +76.20% per trade.
2 Years
xxx
Success Rate
6/17 ratings generated profit
Average Return
+53.07%
reiterated a xxx
rating 2 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 35.29% of your transactions generating a profit, with an average return of +53.07% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
CLDX Analyst Recommendation Trends
Rating
Apr 25
May 25
Jun 25
Jul 25
Aug 25
Strong Buy
6
12
16
15
13
Buy
2
1
3
3
3
Hold
1
8
10
14
8
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
9
21
29
32
24
Each month's total comprises the sum of three months' worth of ratings.
CLDX Financial Forecast
CLDX Stock Forecast FAQ
What is CLDX’s average 12-month price target, according to analysts?
Based on analyst ratings, Celldex Therapeutics Inc’s 12-month average price target is 55.50.
What is CLDX’s upside potential, based on the analysts’ average price target?
Celldex Therapeutics Inc has 122.09% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is CLDX a Buy, Sell or Hold?
Celldex Therapeutics Inc has a consensus rating of Strong Buy which is based on 8 buy ratings, 1 hold ratings and 0 sell ratings.
What is Celldex Therapeutics Inc’s price target?
The average price target for Celldex Therapeutics Inc is 55.50. This is based on 9 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $78.00 ,the lowest forecast is $24.00. The average price target represents 122.09% Increase from the current price of $24.99.
The highest analyst price target is $78.00 ,the lowest forecast is $24.00. The average price target represents 122.09% Increase from the current price of $24.99.
What do analysts say about Celldex Therapeutics Inc?
Celldex Therapeutics Inc’s analyst rating consensus is a Strong Buy. This is based on the ratings of 9 Wall Streets Analysts.
How can I buy shares of CLDX?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.